Pulmatrix (PULM) Competitors

Pulmatrix (NASDAQ:PULM) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, community ranking, analyst recommendations and valuation.

Do insiders & institutionals believe in PULM or PLX?

11.8% of Pulmatrix shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 0.6% of Pulmatrix shares are held by insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Does the media favor PULM or PLX?

In the previous week, Pulmatrix had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 1 mentions for Pulmatrix and 0 mentions for Protalix BioTherapeutics. Pulmatrix's average media sentiment score of 1.87 beat Protalix BioTherapeutics' score of 0.00 indicating that Pulmatrix is being referred to more favorably in the media.

Company	Overall Sentiment
Pulmatrix	Very Positive
Protalix BioTherapeutics	Neutral

Does the MarketBeat Community believe in PULM or PLX?

Pulmatrix received 183 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. However, 81.25% of users gave Protalix BioTherapeutics an outperform vote while only 48.04% of users gave Pulmatrix an outperform vote.

Company	Underperform	Outperform
Pulmatrix	Outperform Votes 196 48.04%	Underperform Votes 212 51.96%
Protalix BioTherapeutics	Outperform Votes 13 81.25%	Underperform Votes 3 18.75%

Which has stronger valuation & earnings, PULM or PLX?

Protalix BioTherapeutics has higher revenue and earnings than Pulmatrix. Pulmatrix is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmatrix	$1.92M	15.81	-$14.12M	-$3.34	-2.49
Protalix BioTherapeutics	$59.76M	2.13	$8.31M	$0.04	40.03

Do analysts rate PULM or PLX?

Protalix BioTherapeutics has a consensus target price of $15.00, suggesting a potential upside of 836.91%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Pulmatrix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmatrix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is PULM or PLX more profitable?

Protalix BioTherapeutics has a net margin of -21.03% compared to Pulmatrix's net margin of -96.51%. Protalix BioTherapeutics' return on equity of -30.89% beat Pulmatrix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmatrix	-96.51%	-45.97%	-30.72%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Which has more risk and volatility, PULM or PLX?

Pulmatrix has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of -0.21, meaning that its stock price is 121% less volatile than the S&P 500.

Summary

Protalix BioTherapeutics beats Pulmatrix on 12 of the 18 factors compared between the two stocks.